OUr Science

Our Pipeline

Rallybio is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The company continues to build a portfolio of product candidates with the potential to eradicate or transform rare diseases.

Program

Lead Indication

Discovery

Preclinical

Early Clinical

Registration Enabling

RLYB211

Fetal and Neonatal Alloimmune Thrombocytopenia

RLYB212

Hematology

RLYB116

Immuno-inflammation

RLYB115

Immuno-inflammation

RLYB114

Immuno-inflammation

RE Ventures

Metabolic

Our Process

At Rallybio, we are building a portfolio of product candidates that target devastating rare disorders with significant morbidity and mortality. Each product candidate must also meet the following criteria:

Therapeutic has potential for transformative clinical and functional impact

Therapeutic is an engineered protein, antibody or small molecule

Therapeutic is late discovery to early clinical stage

Target Disease has Well Understood Pathophysiology

Target Disease affects >3 patients per million

If you are looking to accelerate the development of a product candidate that fits the Rallybio criteria, please contact us here:
  • This field is for validation purposes and should be left unchanged.